ARGOS THERAPEUTICS INC
ARGOS THERAPEUTICS INC (ARGS): 2 pipeline candidates · ~6 mo cash runway. Updated within the last hour.
BioSniper Score
4-factor signal · derived from public data
6.4 months
0% dilution
Lead: Phase 3
2 candidates
N/A
N/A
A transparent, data-derived signal for ARGOS THERAPEUTICS INCacross cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
—
Cash
$7.9M
Quarterly Burn
$3.9M
Runway
6.4 mo
Revenue
$1.2M
Cash Runway vs Catalysts
Tracked catalysts land within the current projected cash runway.
Pipeline (2 candidates)
| Drug | Phase |
|---|---|
| ags-004 | Phase 2 |
| rocapuldencel-t | Phase 3 |
Frequently asked questions
How many drug candidates are in ARGOS THERAPEUTICS INC's pipeline?
ARGOS THERAPEUTICS INC (ARGS) has 2 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.
What is ARGOS THERAPEUTICS INC's lead drug candidate?
ARGOS THERAPEUTICS INC's most advanced tracked candidate is ags-004 (Phase 2) for HIV.
What is ARGOS THERAPEUTICS INC's cash runway?
Based on its most recent reported cash balance and quarterly burn rate, ARGOS THERAPEUTICS INC has approximately 6.4 months of cash runway.
Get the full picture on ARGOS THERAPEUTICS INC
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.